Is RPRX undervalued or overvalued?

As of 2025-03-17, the Intrinsic Value of Royalty Pharma PLC (RPRX) is 42.55 USD. This RPRX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 32.77 USD, the upside of Royalty Pharma PLC is 29.80%. This means that RPRX is undervalued by 29.80%.

The range of the Intrinsic Value is 18.59 - 385.43 USD

	Range	Selected	Upside
a
DCF (Growth 5y)	18.59 - 385.43	42.55	29.8%
DCF (Growth 10y)	23.22 - 418.22	49.19	50.1%
DCF (EBITDA 5y)	49.40 - 100.29	68.31	108.5%
DCF (EBITDA 10y)	49.28 - 107.62	70.67	115.6%
Fair Value	37.25 - 37.25	37.25	13.68%
P/E	29.39 - 39.46	32.77	0.0%
EV/EBITDA	12.64 - 96.15	52.00	58.7%
EPV	(28.02) - (36.64)	(32.33)	-198.7%
DDM - Stable	18.01 - 121.80	69.90	113.3%
DDM - Multi	27.59 - 139.46	45.49	38.8%